Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Genentech, Inc. Clear all
Enrolling by invitation Phase 4 Interventional

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

NCT06495593
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

NCT03024216
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Atezolizumab1200 mg IV, Sipuleucel-T
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Duarte, California • Marina del Rey, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT02457793
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Interventions
Cobimetinib, GDC-0994
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

NCT01397578
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MABT5102A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT01671904
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Obinutuzumab, Rituximab, Venetoclax
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
La Jolla, California • Harvey, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis

NCT00302445
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Efalizumab, Narrow Band Phototherapy
Drug · Device
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Louisville, Kentucky • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2007 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle

NCT04141930
View directory record Official record
Conditions
Influenza, Respiratory Viral Infection
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Months and older
Enrollment
481 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jun 7, 2026, 10:53 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles

NCT02142114
View directory record Official record
Conditions
Pain
Interventions
Eye injection by 30 or 32 gauge needle
Device
Lead sponsor
Retina Health Center
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Jun 7, 2026, 10:53 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06488716
View directory record Official record
Conditions
Solid Tumour
Interventions
RO7759065, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Duarte, California • Aurora, Colorado • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 7, 2026, 10:53 AM EDT
Terminated Phase 1 Interventional

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

NCT02298153
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
Interventions
Epacadostat, Atezolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 7, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

NCT00529503
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Interventions
SGN-40, placebo, rituximab, etoposide, carboplatin, ifosfamide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Jun 7, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

NCT02291887
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Aflibercept
Drug
Lead sponsor
Associated Retinal Consultants, Michigan
Other
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

NCT00805233
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
combination ranibizumab + bromfenac, ranibizumab injection alone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional

Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

NCT00642655
View directory record Official record
Conditions
Kidney Transplant
Interventions
IVIG and Rituximab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Jun 7, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

NCT03473340
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions
Pirfenidone Capsule, Placebo Capsule
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jun 7, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

NCT03311126
View directory record Official record
Conditions
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
Interventions
Bendamustine, Obinutuzumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Viral Kinetics in HCV Clearance in Subjects With Hemophilia

NCT01704521
View directory record Official record
Conditions
Chronic Hepatitis C, Hemophilia
Interventions
PegInterferon, Ribavirin, Telaprevir
Drug
Lead sponsor
Kenneth Sherman
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

NCT01546519
View directory record Official record
Conditions
Cancer
Interventions
Vismodegib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer

NCT00047736
View directory record Official record
Conditions
Lung Cancer
Interventions
Tarceva (erlotinib HCl)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

RAD001 Plus Bevacizumab in Metastatic Melanoma

NCT00591734
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Bevacizumab, Everolimus
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jun 7, 2026, 10:53 AM EDT
Terminated No phase listed Observational

Study Evaluating Genotypes Using Lucentis

NCT00474695
View directory record Official record
Conditions
Age-Related Maculopathy
Interventions
Lucentis
Drug
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Santa Barbara, California • Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Jun 7, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

NCT03221257
View directory record Official record
Conditions
Scleroderma, Systemic, Interstitial Lung Disease
Interventions
Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Jun 7, 2026, 10:53 AM EDT
Withdrawn Phase 2 Interventional

Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

NCT01427244
View directory record Official record
Conditions
Paget's Disease of the Vulva
Interventions
trastuzumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Jun 7, 2026, 10:53 AM EDT
Not yet recruiting Not applicable Interventional

Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis

NCT07181811
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments
Other
Lead sponsor
Anza Memon
Federal
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jun 7, 2026, 10:53 AM EDT